An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant

References

• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588–1593.
   PubMed Web of Science ®Google Scholar
• Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2535–2542.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung H, et al. Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation? Biol Blood Marrow Transplant 2006;12:641–647.
   PubMed Web of Science ®Google Scholar
• Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49:1062–1073.
   PubMed Web of Science ®Google Scholar
• Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010;10:54–61.
   PubMed Web of Science ®Google Scholar
• Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23:6117–6125.
   PubMed Web of Science ®Google Scholar
• Dasgupta RK, Adamson PJ, Davies FE, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003;102:2345–2350.
   PubMed Web of Science ®Google Scholar
• Jun L, Haiping Z, Beibei Y. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 2009;139:724–728.
   PubMed Web of Science ®Google Scholar
• Chen YC, Tzeng CH, Chen PM, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2010;101:530–535.
   PubMed Web of Science ®Google Scholar
• Terakura S, Murata M, Nishida T, et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant 2006;37:381–386.
   PubMed Web of Science ®Google Scholar
• Jones BA, Christensen AR, Wise JP Sr, Yu H. Glutathione S-transferase polymorphisms and survival in African-American and White colorectal cancer patients. Cancer Epidemiol 2009;33:249–256.
   PubMed Web of Science ®Google Scholar
• Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006;24:5645–5651.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007;120:1036–1045.
   PubMed Web of Science ®Google Scholar
• Brem R, Hall J. XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 2005;33:2512–2520.
   PubMed Web of Science ®Google Scholar
• Iarmarcovai G, Sari-Minodier I, Chaspoul F, . Risk assessment of welders using analysis of eight metals by ICP-MS in blood and urine and DNA damage evaluation by the comet and micronucleus assays; influence of XRCC1 and XRCC3 polymorphisms. Mutagenesis 2005;20:425–432.
   PubMed Web of Science ®Google Scholar
• Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 2007;21:1413–1422.
   PubMed Web of Science ®Google Scholar
• Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008;49:204–217.
   PubMed Web of Science ®Google Scholar
• Qu T, Morii E, Oboki K, Lu Y, Morimoto K. Micronuclei in EM9 cells expressing polymorphic forms of human XRCC1. Cancer Lett 2005;221:91–95.
   Google Scholar
• Kim YJ, Choi JY, Paek D, Chung HW. Association of the NQO1, MPO, and XRCC1 polymorphisms and chromosome damage among workers at a petroleum refinery. J Toxicol Environ Health A 2008;71:333–341.
   PubMed Web of Science ®Google Scholar
• Leng S, Cheng J, Pan Z, et al. Associations between XRCC1 and ERCC2 polymorphisms and DNA damage in peripheral blood lymphocyte among coke oven workers. Biomarkers 2004;9:395–406.
   PubMed Web of Science ®Google Scholar
• Musak L, Vodicka P, Klimentova G, et al. Chromosomal damage and polymorphisms of DNA repair genes XRCC1 and XRCC3 in workers exposed to cytostatics. Neuro Endocrinol Lett 2006;27(Suppl. 2):57–60.
   PubMed Web of Science ®Google Scholar
• Liu B, Wei J, Zou Z, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007;15:1049–1053.
   PubMed Web of Science ®Google Scholar
• Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009;9:347–353.
   PubMed Web of Science ®Google Scholar
• Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761–3766.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–3279.
   PubMed Web of Science ®Google Scholar
• Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006;22:1928–1929.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002;8:9–16.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Hamajima N, Suzuki R, et al. Lack of association between DNA base excision repair gene XRCC1 Gln399Arg polymorphism and risk of malignant lymphoma in Japan. Cancer Genet Cytogenet 2004;149:77–80.
   PubMed Web of Science ®Google Scholar